NCT00040053

Ondansetron for the Treatment of Methamphetamine Dependence - 1

Double-Blind, Placebo-Controlled, Dose Response Trial of Ondansetron for the Treatment of Methamphetamine Dependence.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 154 (planned)
• Sponsor: National Institute on Drug Abuse (NIDA) · NIH
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.

Detailed description

This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.

Conditions

• Amphetamine-Related Disorders

Interventions

Type	Name	Description
DRUG	Ondansetron

Timeline

• Start date: 2002-06-01
• Completion: 2004-02-01
• First posted: 2002-06-18
• Last updated: 2017-01-12

Locations

6 sites across 1 country: United States